Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses The patients included in this ...
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non–Small-Cell Lung Cancer Undetectable MRD (uMRD) was assessed by next-generation sequencing at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback